Quality Assurance & Regulatory Specialist
✓ Reviewed by: Pankaj Sharma - Quality Control Specialist
Reviewed for Quality Control accuracy, laboratory practices, analytical methods, and technical relevance
📅 Last Updated: October 28, 2026
What is media fill in pharmaceutical manufacturing? It is aseptic process simulation (APS), a test in which sterile nutrient medium replaces the product and goes through the whole aseptic process, interventions included. The filled units are incubated and inspected for growth, and EU GMP Annex 1 sets the target at zero growth. APS is a periodic verification, not the main proof that an aseptic process is validated. The sections below cover run design, limits, repeat schedule and the response to a failure.
What Is Media Fill in Pharmaceutical?
Media fill is a full rehearsal of a sterile filling operation. The product is replaced by a liquid that microbes grow in easily, while the line, people, gowning and interventions stay the same as in production. If a microbe gets into a unit, the medium turns cloudy during incubation.
Many sterile products can’t be heated in their final container, so they are filled aseptically. Their sterility then depends on air quality, equipment and operator behaviour, not on a last sterilisation step. Media fill shows whether those controls hold up across a full run.
Definition of Aseptic Process Simulation (APS)
EU GMP Annex 1 (2022 revision) heads this topic “Aseptic process simulation (APS) (also known as media fill)”. Para 9.32 describes a test that uses sterile nutrient media and/or a surrogate in place of the product, run as a periodic verification. Annex 1 states that it is not the primary means of validating the aseptic process.
How Does Media Fill Work?
A media fill copies routine production as closely as possible, then lets the incubated units reveal any contamination. PIC/S PI 007-6 (2011), section 4.1.1, says the run should emulate the regular fill in equipment, processes, personnel, and the time taken for filling and holding.
The design must also cover the hard days. PI 007-6 section 5.1.2 asks for a worst-case situation that includes all manipulations and interventions likely during a shift. Annex 1 adds the longest run, shift changes and campaign start and end. Choose interventions through a documented risk assessment, covering both routine and corrective ones.
Environmental and personnel monitoring runs during the whole simulation, exactly as in production (Annex 1, 9.36(xi)). Don’t prepare the room more carefully than you would for a real batch. The run should show everyday performance, not a best effort.
Read more: media fill interventions and worst-case design
Main Components of a Media Fill Run
Culture Medium
Purpose: gives any entering microbe something to grow on, so contamination becomes visible.
The usual choice is soybean casein digest medium (SCDM), also sold as tryptic soy broth (TSB). It supports many kinds of organisms and stays clear, so growth is easy to see. The FDA 2004 guidance names it as a typical medium. Suppliers prepare it at about 3% w/v, and certificates typically give a pH near 7.3 ± 0.2 at 25 °C. Neither Annex 1 nor FDA sets a media fill pH limit, so the site fixes its limit in the SOP from the supplier’s certificate.
Before use, the medium passes a growth promotion test. Annex 1 para 10.9 asks for a justified group of reference organisms that includes representative local isolates. PIC/S PI 007-6 (5.2.3) wants recovery of low numbers, 10-100 CFU per unit or fewer. Anaerobic medium such as fluid thioglycollate is considered only in special circumstances.
Read more: SCDM, TSB and growth promotion in media fill
Units and Containers
Purpose: carries the medium through the same filling and closing steps as the product.
Use the production container-closure and a fill volume set in the protocol. Choose clear containers, not amber or opaque ones, so growth can be seen. Invert or agitate the units before incubation so the medium touches every inner surface, closure included.
People and Interventions
Purpose: tests the human part of the process, usually the largest contamination risk.
Operators who normally work on the line do the run. Record every intervention with its start time, end time and the person involved. A QC analyst or quality unit representative observes the run, and FDA notes that video recording can help show poor personnel practice.
How Is a Media Fill Done? Step-by-Step Process Flow
- Approve the protocol. The QA officer signs the protocol listing line, shifts, container sizes, fill volume, interventions, unit count and acceptance criteria.
- Prepare and test the medium. Prepare the SCDM. Perform growth promotion testing (GPT) using reference organisms and environmental isolates. Media must be qualified before use, with units from the start and end of the filling run validated for GPT post-incubation.
- Set up the line. Gown and prepare the area as for routine production and start environmental and personnel monitoring.
- Fill with interventions. Run the line for the planned duration and perform each listed intervention.
- Reconcile units. Account for every unit filled, rejected or removed. Annex 1 para 9.47 requires this, and no more units may be removed than in routine production.
- Incubate. FDA 2004 says incubation should not be less than 14 days. If two temperatures are used, hold at least 7 days at each, lower first, within 20-35 °C.
- Inspect and identify. Trained, qualified staff inspect the units. Samples undergo positive control (Annex 1, 9.45(ii)), and isolates are identified to species level.
- Report and decide. QA approves the report, and the quality unit decides on batch disposition for the line.
Read more: media fill procedure and protocol, step by step and incubation conditions and inspection
Where Is Media Fill Used?
Every aseptic filling process needs it. That covers liquids in vials, ampoules and syringes, products such as vaccines (see the vaccine filling procedure), lyophilised products, powders and semi-solids.
Powders and semi-solids can’t flow like broth, so the simulation uses a surrogate. Lyophilised products need the loading and transfer steps simulated. If production uses nitrogen or another inert gas, Annex 1 (9.33(iii) and 9.36(v)) expects air in the APS unless an anaerobic simulation is intended.
Isolator and RABS lines still need APS. ISO 13408-6:2021 covers isolator systems, and FDA lets isolator-based operations simulate a lower proportion of units.
Read more: media fill for powders, lyophilized products, isolators and RABS
What Are the Benefits of Media Fill?
Media fill tests the whole process under realistic conditions, not one machine in isolation. It exposes weak interventions and training gaps before they reach a batch. The records also give inspectors direct evidence that the contamination control strategy (CCS), the site’s overall plan for keeping microbes out, works in practice.
What Are the Limitations of Media Fill?
A clean run doesn’t prove that every batch is sterile. It samples one period of performance with a limited number of units. Annex 1 (9.1) warns that viable monitoring, non-viable monitoring and APS data are each limited when taken alone. Treat APS as one strand of evidence beside process validation and routine monitoring.
Key Operating Parameters for Media Fill
| Parameter | Typical requirement | Source |
|---|---|---|
| Initial qualification | At least 3 consecutive satisfactory runs covering all working shifts | Annex 1, 9.38 |
| Repeat frequency | Normally twice a year (about every 6 months) for each aseptic process, filling line and shift | Annex 1, 9.38; FDA 2004 semi-annual; PI 007-6 5.5 |
| Operator qualification | At least 1 successful APS per operator each year; manual operations: 3 consecutive initially, then about every 6 months | Annex 1, 9.38 and 9.39; FDA annual for each person authorised to enter |
| Run size | 5,000-10,000 units as a starting point; a batch under 5,000 units needs a run at least equal to the maximum batch size | FDA 2004 |
| Incubation | At least 14 days; two temperatures: at least 7 days each, lower first, within 20-35 °C | FDA 2004; PI 007-6 5.3.1 gives 20-25 °C then 30-35 °C |
| Acceptance | Target is zero growth | Annex 1, 9.46 |
Exact values depend on the guidance you follow and your approved protocol. Annex 1 (9.44) leaves incubation conditions and duration to scientific justification and validation.
Worked example: a site fills 10,000 units. Under the FDA table, zero contaminated units passes. One contaminated unit means investigation and consideration of a repeat. Two mean revalidation after investigation. Under Annex 1, that single unit already fails the APS.
Read more: media fill acceptance criteria and media fill frequency and requalification
Industry Standards and Regulatory Requirements
| Document | Status | What it says about APS |
|---|---|---|
| EU GMP Annex 1 (revised August 2022, applicable 25 August 2023) | Part of EU GMP | Section 9: zero growth target, 3 initial runs, six-monthly repeats, failure actions |
| FDA, Sterile Drug Products Produced by Aseptic Processing (September 2004) | Non-binding guidance | Unit-count table, run size, 14-day incubation; supports 21 CFR 211.113(b) |
| PIC/S PI 007-6 (2011) | Inspectorate recommendation | Worst case, growth promotion, incubation, same unit-count criteria in section 6.2 |
| WHO TRS 1044, Annex 2 (2022) | WHO GMP for sterile products | Reference text for WHO-aligned markets |
| ISO 13408-1:2023 | International standard | General requirements for aseptic processing of health care products |
Read more: media fill guidelines from WHO, PIC/S, FDA and Annex 1 compared
Recent Technology Trends
August 2023: Annex 1 became applicable on 25 August 2023, with the lyophiliser paragraph 8.123 following a year later. It ties APS to the CCS, and inspectors now judge APS against it.
August 2023: ISO 13408-1:2023 was published and replaced the 2008 edition and its 2013 amendment, according to the AFNOR listing.
October 2022: WHO published TRS 1044, Annex 2, its current GMP text for sterile pharmaceutical products.
October 2025: PDA’s bookstore lists Technical Report No. 22 (Revised 2025), Process Simulation for Aseptically Filled Products, as replacing the 2011 edition.
January 2026: A vendor brochure on Pharmaceutical Online describes robotic, recipe-driven filling workcells with gloveless isolators. Fewer manual interventions would leave fewer to simulate. This is vendor material, not a regulator view.
Common Problems and Troubleshooting in Media Fill
What Happens When a Media Fill Fails?
Any contaminated unit fails the APS under Annex 1 (9.46). A failed APS leads to investigation, corrective measures, repeat APS and batch impact assessment, not just a rerun. The QA officer opens a deviation, and CAPA tracks the fixes.
- Investigate the root cause. Identify isolates to species level and compare them with environmental and personnel monitoring isolates.
- Apply corrective measures.
- Repeat the APS. Annex 1 normally expects a minimum of three consecutive successful repeats.
- Review records since the last successful APS. FDA expects the impact on commercial product made since the last media fill to be assessed.
- Quarantine product made on the line after the failure.
- Restrict the operators involved until they are retrained and requalified.
- Resume production only after revalidation.
Other Frequent Problems
| Problem | Likely cause | Action |
|---|---|---|
| Unit count doesn’t reconcile | Units dropped or discarded at line end without a record | Count at each stage and justify every unit not incubated |
| Incubator outside range | Door openings, faulty controller | Review the temperature log, assess the run, and keep the temperature within the validated range (FDA: ±2.5 °C of target) |
| Run judged unrepresentative | Interventions missing from the record or protocol | Update the intervention list from the risk assessment and repeat |
In practice, the missing intervention is rarely an exotic one. It’s usually the routine stopper refill that nobody wrote down.
Read more: media fill failure investigation, root cause and CAPA
How Do You Keep Media Fill Status Current?
Schedule repeats well ahead of the six-month point for each line and shift. Annex 1 (9.38 and 9.49) and FDA also call for repeat qualification after significant changes to HVAC, equipment, process, shifts or personnel. They also call for it after an extended shutdown and for a new container-closure. Route these triggers through change control.
Keep protocols, intervention lists, incubation logs and inspection records to ALCOA+ standards: attributable, legible, contemporaneous, original and accurate, plus complete, consistent, enduring and available. Operator qualification records belong in the training records.
Expert Tips
- Match the real shift. Use the same crew size, gowning and break pattern as production.
- List every intervention first. Include rare corrective ones from the risk assessment, and record start time, end time and person.
- Keep the area routine. Don’t add extra cleaning and sanitisation before the run.
- Reconcile as you go. Count units at the filling machine, at inspection and at the incubator.
- Use clear containers. Amber or opaque units hide early turbidity.
- Treat incubation logs as GMP records. Gaps in temperature data weaken an otherwise clean run.
Frequently Asked Questions
Aseptically filled products have no final sterilisation step to remove contamination, so the process itself must be shown to keep microbes out. Media fill gives that evidence under realistic conditions. EU GMP Annex 1 requires APS, and the FDA guidance, which supports 21 CFR 211.113(b), sets matching expectations for US manufacturers.
Annex 1 para 9.38 asks for three consecutive satisfactory runs covering all working shifts at initial validation. After that, repeat normally twice a year, about every six months, for each aseptic process, filling line and shift. Each operator needs at least one successful APS annually. Major changes and failures trigger extra runs.
SCDM (TSB) is the usual medium because it supports many organisms, dissolves well and stays clear. About 3% w/v is the standard strength suppliers use when preparing the broth. Annex 1 and FDA don’t set a concentration, so the site records the strength in its approved protocol and media specification.
Annex 1 para 9.46 sets a zero growth target, and any contaminated unit fails the APS. FDA’s non-binding table is graded by run size. For 5,000-10,000 units, one contaminated unit means investigation and possible repeat, and two mean revalidation. Over 10,000 units, one means investigation and two mean revalidation.
FDA 2004 says incubate for not less than 14 days within 20-35 °C. With two temperatures, hold at least 7 days at each, lower first. PIC/S PI 007-6 describes 20-25 °C for at least 7 days, then 30-35 °C, for 14 days in total. Annex 1 para 9.44 requires justified and validated conditions.
No regulator sets one. The limit comes from the medium supplier’s certificate of analysis, and for SCDM powder a typical value is about 7.3 ± 0.2 at 25 °C. The site writes the limit into its SOP. Growth promotion testing then shows that the prepared medium performs as intended.
A sterility test examines a small sample of finished product and can’t prove a whole batch is sterile. Media fill challenges the process itself, using growth medium across many units with realistic interventions. The two answer different questions, and neither replaces the other.
Read more: media fill interview questions and answers
Summary
Media fill, or aseptic process simulation, runs sterile nutrient medium through the whole aseptic process to show it keeps microbes out. Annex 1 targets zero growth, expects repeats about every six months, and requires a full investigation after any failure. Treat it as periodic verification, supported by monitoring and good practice.
References
- EU GMP Annex 1: Manufacture of Sterile Medicinal Products (2022), European Commission
- Sterile Drug Products Produced by Aseptic Processing: Current Good Manufacturing Practice (2004), US FDA
- PI 007-6 Recommendation on the Validation of Aseptic Processes (2011), PIC/S
- TRS 1044, Annex 2: WHO good manufacturing practices for sterile pharmaceutical products, WHO
- ISO 13408-1:2023 Aseptic processing of health care products, Part 1 (AFNOR listing)
- ISO 13408-6:2021 Aseptic processing of health care products, Part 6: Isolator systems (AFNOR listing)
- Technical Report No. 22 (Revised 2025), PDA
- Meet the Aseptic Filling Workcell, Pharmaceutical Online (vendor brochure)
- Aseptic Process Simulation (APS), Merck/Sigma-Aldrich
Satpal Singh — Quality Assurance & Regulatory Specialist
Satpal Singh is an experienced pharmaceutical Quality Assurance and Regulatory professional with expertise in GMP compliance, quality systems, technical documentation, and regulatory requirements. He reviews our pharmaceutical content to ensure accuracy, industry relevance, and alignment with current quality and regulatory standards.
Expertise: QA Systems | GMP Compliance | Regulatory Documentation | Audits | Quality Management